ACADIA Pharmaceuticals Inc.
ACAD
Rangering i aksjer
#4431
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aksjekurs
$20.43
Markedsverdi
$3.52B
Endring (1 dag)
3.16%
Endring (1 år)
-2.46%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
P/B-forhold for ACADIA Pharmaceuticals Inc. (ACAD)
P/B-forhold per October 2026 TTM: 2.53
Ifølge ACADIA Pharmaceuticals Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 2.53. Ved slutten av 2023 hadde selskapet et P/B-forhold på 11.88.
P/B-historikk for ACADIA Pharmaceuticals Inc. fra 2000 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 2.53 | -39.08% |
| 2024 | 4.15 | -65.07% |
| 2023 | 11.88 | 84.80% |
| 2022 | 6.43 | -7.18% |
| 2021 | 6.93 | -48.37% |
| 2020 | 13.41 | 48.93% |
| 2019 | 9.01 | 110.82% |
| 2018 | 4.27 | -61.19% |
| 2017 | 11.01 | 70.82% |
| 2016 | 6.45 | -64.11% |
| 2015 | 17.96 | 80.01% |
| 2014 | 9.98 | -15.17% |
| 2013 | 11.76 | 291.77% |
| 2012 | 3.00 | 24.44% |
| 2011 | 2.41 | 54.65% |
| 2010 | 1.56 | -61.80% |
| 2009 | 4.08 | 547.88% |
| 2008 | 0.63 | -81.58% |
| 2007 | 3.42 | -6.39% |
| 2006 | 3.65 | -33.64% |
| 2005 | 5.51 | 141.07% |
| 2004 | 2.28 | -1,330.93% |
| 2003 | -0.19 | -23.53% |
| 2002 | -0.24 | -153.56% |
| 2001 | 0.45 | -242.26% |
| 2000 | -0.32 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | 147.25% |
US
|
|
| 13.2547 | 424.27% |
US
|
|
| 4.208 | 66.44% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 144.54% |
NL
|
